^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IN01

i
Other names: IN01
Associations
Trials
Company:
In3Bio
Drug class:
Immunostimulant, EGF inhibitor
Related drugs:
Associations
Trials
over2years
Anti-EGF antibodies significantly improve the activity of BRAF and KRAS inhibitors in preclinical models (AACR 2022)
In this study, we tested if antibodies generated by vaccination with IN01 (biologic fusion molecule), could improve the antitumor activity of encorafenib and sotorasib in BRAF and KRAS colorectal (CRC) and non-small cell lung cancer (NSCLC) cell lines. Cell lines with BRAF V600E (HT29, CRC) and KRAS G12C mutations (H2122 and H23, NSCLC) were used. Anti-EGF VacAbs potentiate the antitumor effects of encorafenib and sotorasib in cancer cell lines more efficiently than cetuximab and panitumumab. Our data provide a rationale for clinical trials testing the combination of anti-EGF VacAbs with targeted inhibitors in BRAF and KRAS mutant CRC and NSCLC patients. (1)“Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells” García-Roman S, Molina-Vila MA, et al.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • AKT1S1 (AKT1 Substrate 1)
|
BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • ALK rearrangement • KRAS G12
|
Erbitux (cetuximab) • Vectibix (panitumumab) • Lumakras (sotorasib) • Braftovi (encorafenib) • IN01